Expertise in
14
conditions

Dr. Merrill K. Shum

Internal Medicine
Oncology Physicians Network Of California PC
8135 Painter Ave, 
Whittier, CA 
Offers Telehealth
Expertise in
14
conditions
Oncology Physicians Network Of California PC
8135 Painter Ave, 
Whittier, CA 

Overview

Merrill Shum is a primary care provider, practicing in Internal Medicine in Whittier, California.

Dr. Shum is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Multiple Myeloma.

Dr. Shum is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 14 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in PA

Board Certifications

American Board Of Internal Medicine

Fellowships

Cancer Institute Of New Jersey At Cooper , Hematology & Oncology , 2004 - 2007

Hospital Affiliations

Pih Health Downey Hospital
Whittier Hospital Medical Center
Pih Health Hospital-Whittier

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Oncology Physicians Network Of California Pc
8135 Painter Ave, Whittier, CA 90602
Other Locations
Oncology Physicians Network Of California Pc
23600 Telo Ave, Torrance, CA 90505
Oncology Physicians Network Of California Pc
16315 Whittier Blvd, Whittier, CA 90603

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 1 Multiple Dose, Dose Escalation Trial of AEB1102 (Co-Arg1-PEG) in Patients With Advanced Solid Tumors
A Phase 1 Multiple Dose, Dose Escalation Trial of AEB1102 (Co-Arg1-PEG) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: August 06, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
Enrollment Status: Completed
Publish Date: April 13, 2026
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Drug
Study Drugs: Itacitinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brigatinib, Alectinib
Study Phase: Phase 3
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

2 Total Publications

Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia.
Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia.
Journal: Blood
Published: September 15, 2023
Similar Doctors
Expertise in
20
conditions
Dr. Raymond T. Chung
Internal Medicine
Expertise in
20
conditions
Dr. Raymond T. Chung
Internal Medicine

Orange County - Anaheim Medical Center

3440 E La Palma Avenue, 
Anaheim, CA 
 (13.4 miles away)
833-574-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Raymond Chung is a primary care provider, practicing in Internal Medicine in Anaheim, California. Dr. Chung is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, Cirrhosis, Liver Transplant, and Kidney Transplant. Dr. Chung is currently accepting new patients.

Expertise in
28
conditions
Dr. Michael H. Albert
Internal Medicine
Expertise in
28
conditions
Dr. Michael H. Albert
Internal Medicine

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (21.4 miles away)
310-423-5161
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Albert is a primary care provider, practicing in Internal Medicine in West Hollywood, California. Dr. Albert is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Nijmegen Breakage Syndrome, Wiskott-Aldrich Syndrome, Hyper IgE Syndrome, Splenectomy, and Bone Graft. Dr. Albert is currently accepting new patients.

Expertise in
18
conditions
Dr. Charles N. Bernstein
Internal Medicine
Expertise in
18
conditions
Dr. Charles N. Bernstein
Internal Medicine

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (24.6 miles away)
310-794-9718
Languages Spoken:
English

Charles Bernstein is a primary care provider, practicing in Internal Medicine in Los Angeles, California. Dr. Bernstein is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Viral Gastroenteritis, Crohn's Disease, Colitis, Colonoscopy, and Endoscopy.

Frequently Asked Questions about Dr. Merrill K. Shum

How do I make an appointment with Dr. Merrill K. Shum?

You can book an appointment with Dr. Merrill K. Shum by calling their office at 562-698-6888. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Merrill K. Shum a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Merrill K. Shum is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Merrill K. Shum specialize in?

While Dr. Merrill K. Shum is a Internal Medicine, they have specific expertise in Breast Cancer, Colorectal Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Merrill K. Shum participate in research or clinical trials?

Yes. Dr. Merrill K. Shum has published 2 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Merrill K. Shum's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Merrill K. Shum accept my insurance?

Dr. Merrill K. Shum accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 562-698-6888 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shum's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 90 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile